Death of a Drug: The Aftermath of Merck’s Recall

Wharton management professor Michael Useem director of the school’s Center for Leadership and Change Management notes that one of the key mantras in corporate crisis management is: ”Hide nothing tell all.” Less than a week after Merck & Co.’s voluntary withdrawal of its blockbuster arthritis pain medication Vioxx following an extended clinical trial that linked the drug to heart attacks and strokes the jury is still out on whether the pharmaceutical giant followed this cardinal rule. Wharton professors debate Merck’s response to the crisis and the impact of the recall. Hosted on Acast. See acast.com/privacy for more information.